Posters & Abstracts

Posters & Abstracts

  1. NANT Cancer Vaccine (NCV): An Orchestration of Immunogenic Cell Death by Overcoming Immune Suppression and Activating Natural Killer (NK) and T Cell Therapy in Patients with Greater than 3rd Line Metastatic Pancreatic Cancer
    Tara Seery, Arvind Shinde, Mira Kistler, Lennie Sender, Anand Annamalai, Omid Jafari, Frank Jones, John H. Lee, Patrick Soon-Shiong
    Jan 2019

    2.  

  2. NANT Cancer Vaccine (NCV): An Orchestration of Immunogenic Cell Death by Overcoming Immune Suppression and Activating Natural Killer (NK) and T Cell Therapy in Patients with Greater Than 3rd-Line Triple-Negative Breast Cancer (TNBC) or Head and Neck Squamous Cell Carcinoma (HNSCC)
    Chaitali Nangia, Mira Kistler, Lennie Sender,  John H. Lee, Frank Jones, Patrick Soon-Shiong
    Nov 2018

    3.  

  3. NANT Cancer Vaccine (NCV): An Orchestration of Immunogenic Cell Death by Overcoming Immune Suppression and Activating Natural Killer (NK) and T Cell Therapy in Patients with Greater than 3rd Line Metastatic Pancreatic Cancer
    Tara Seery, Arvind Shinde, Mira Kistler, Lennie Sender, Anand Annamalai, Omid Jafari Frank Jones, John H. Lee, Patrick Soon-Shiong
    Nov 2018

    4.  

  4. Adoptive Cellular Therapy (ACT) With Allogeneic Activated Natural Killer (aNK) Cells in Patients With Advanced Merkel Cell Carcinoma (MCC): Preliminary Results of a Phase 2 Trial
    Shailender Bhatia, Melissa Burgess, Hui Zhang, Tien Lee, Hans Klingemann, Patrick Soon-Shiong, Paul Nghiem, John M. Kirkwood

    5.  

  5. Development of an IL-2 independent NK cell line expressing high-affinity Fc-receptor to augmentmonoclonal antibody therapy   Laurent Boissel, Kerry S. Campbell, Ashley M. James, Frances Toneguzzo, Hans Klingemann
    Conkwest, Inc., Cardiff-by-the-Sea, CA USA;  Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA USA

    6.  

  6. A GMP-Grade IL-2 Independent NK Cell Line Expressing The High-affinity Fc-receptor (haNK) to Augment Antibody Therapeutics: Combination of haNK® With Anti-CD38 Monoclonal Antibody (Daratumumab) In Multiple Myeloma Boissel L, Klingemann H, Campbell K, Nichols K, Toneguzzo F, Khan J, Marcus, P, Williams BA, Keating A, and Soon-Shiong P, NantKwest, Inc., Cambridge, MA, USA; Fox Chase Cancer Center, Philadelphia, PA, USA; Princess Margaret Cancer Centre, Toronto, ON, Canada; NantKwest, Inc., Culver City, CA, USA; University California Los Angeles, CA, USA

    7.  

  7. Targeted NK cells display potent activity against glioblastoma and induce protective antitumor immunity
    Congcong Zhang, Michael C. Burger, Lukas Jennewein, Anja Waldmann, Michel Mittelbronn, Torsten Tonn, Joachim P. Steinbach, Winfried S. Wels
    Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany; Institute for Neurooncology, Goethe University, Frankfurt am Main, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Frankfurt am Main, Germany; Edinger Institute, Goethe University, Frankfurt am Main, Germany; German Red Cross Blood Donation Service North-East, Dresden, Germany.

    8.  

  8. haNK, a cytotoxic human high affinity natural killer cell line, exerts enhanced ADCC mediated by avelumab (an anti-PD-L1 antibody) against multiple human tumor cell lines
    Kwong Y. Tsang, Massimo Fantini, James W. Hodge, Rika Fujii, Ingrid Fernando, Caroline Jochems, Christopher R. Heery, James L. Gulley, Patrick Soon-Shiong, Jeffrey Schlom.
    Laboratory of Tumor Immunology and Biology and Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; NantKwest, Culver City, CA.

    9.  

  9. Preclinical characterization of a novel monoclonal antibody targeting a neo-antigen expressed in ovarian and GI malignancies
    Kristen Zeligs, Philip M. Arlen, Kwong Tsang, Lidia Hernandez, Massimo Fantini, Christina M. Annunziata.
    Walter Reed National Military Medical Center, Bethesda, MD; Precision Biologics, Inc., Rockville, MD; National Cancer Institute, Bethesda, MD.

    10.  

  10. CD19 Target Activated Natural Killer (CD19.taNK) Cellular Therapy: A Novel immunotherapeutic Approach to the Treratment of Non-Hodkin Lymphoma (NHL)
    Ravi Dashnamoorthy, Afshin Beheshti, Saheli Sarkar, Pooja Sabhachandani, Frank C. Passero Jr., Sneha Purvey, Laurent Boissel, Tania Konry and Andrew M Evens
    Dec 2015

    11.  

  11. Novel Protocol Combining Metronomic Nant-Paclitaxel with HER2-Targeted Natural Killer Cells (innate Immunotherapy) for HER2 Positive Metastatic Breast Cancer
    Shahrooz Rabizadeh, Barry Simon, Hans Klingemann, Deborah Sims, Raymond Weiss, Patrick Soon-Shiong
    Dec 2015

    12.  

  12. NK-92: An “off the shelf” target-specific cytotoxic cell therapeutic
    Boissel L, Campbell, KS. Toneguzzo F, Nichols K and Klingemann H poster)
    Jun 2015

    13.  

  13. An “off the shelf,” GMP-grade, IL-2-independent NK cell line expressing the high-affinity Fc-receptor to augment antibody theapeutics
    Laurent Boissel, Hans Klingemann, Kerry Campbell, Karen Nichols, Frances Toneguzzo, Paula Marcus, Brent Williams, Armand Keating, & Patrick Soon-Shiong
    Apr 2016

    14.  

  14. Creating NK cell therapeutics with multiple targeting activities: Electroporation of mRNA for Chimeric Antigen Receptors (CARs) into human effecto cell lines
    Junaid Khan, Laurent Boissel, Hans Klingemann, Frances Toneguzzo, Patrick Soon-Shiong
    Oct 2016

    15.  

  15. Optimizing allogeneic natural killer cell reactivity by gene knock-out/knock-down of inhibitory receptors
    Francisco Navarro
    Oct 2016

    16.  

  16. Combination Therapy with Daratumumab and CAR-NK Targeting CS1 for Multiple Myeloma
    Yibo Zhang, Lichao Chen, Yufeng Wang, Xinxin Li, Tiffany Hughes, Hans Klingemann, Don M. Benson and Jianhua Yu
    Dec 2016

    17.  

  17. Natural Killer cells blaze into immuno-oncology
    Hans Klingemann
    Mar 2016

    18.  

  18. Intra-tumor injection of CAR-engineered NK cells induces tumor regression and protection against tumor re-challenge
    Laurent Boissel, Hans Klingemann, Junaid Khan, Patrick Soon-Shiong
    Oct 2016

    19.  

  19. Using unmodified & engineered Natural Killer cell lines in cancer treatment
    Laurent Boissel
    Oct 2016

    20.  

  20. Off the Shelf, Engineered Allogeneic Natural Killer Cell Therapeutics: aNK, haNK, taNK
    Hans Klingemann
    Sep 2016

    21.  

  21. What is the future for NK Cells
    Hans Klingemann
    Sep 2016

    22.  

  22. Cytotherapy with targeted allogeneic NK cells
    Hans Klingemann, Laurent Boissel
    Aug 2017

    23.  

  23. aNK & haNK for Cancer Treatment
    Hans Klingemann
    Dec 2017

    24.  

  24. Off the Shelf, Engineered Allogeneic Natural Killer Cell Therapeutics: aNK, haNK, taNK
    Hans Klingemann
    Feb 2017

    25.  

  25. Adoptive T Cell Therapy track
    Hans Klingemann
    May 2017

    26.  

  26. aNK & haNK for Cancer Treatment
    Hans Klingemann
    Sep 2017

    27.  

  27. CD19 Chimeric Antigen Receptor (CAR) Engineered Natural Killer (NK) Cell Therapy: Novel “Off the Shelf” Immunotherapy in CD20 Resistant Bcell NonHodgkin Lymphoma (NHL) Cell Lines and a Human Lymphoma
    Xenograft Model
    Sneha Purvey, Ravi Dashnamoorthy, Afshin Beheshti, Andreas Klein, Laurent Boissel,Saheli Sarkar, Tali Konry, and Andrew M Evens
    Dec 2017
NantKwest-NK-92-Authenticity-Stamp

CONTACT NANTKWEST

line
Brink-Biologics-NK-92-Authenticity-Stamp

NK-92 ®️ CELLS FOR ASSAYS